Prof. Fortunato Ciardiello, MD, PhD, Seconda Università di Napoli

ASCO 2014, Chicago, June 2: Prof. Fortunato Ciardiello, MD, PhD, Seconda Università di Napoli: Statement about latest results from the CRYSTAL study (Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab) and from CALGB/SWOG 80405 (CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC):